Wednesday, July 8, 2026

Patent intelligence · US

US 11535869

CD8-specific antibody constructs and compositions thereof

granted A61KA61K2039/505A61K2039/545A61K2239/31
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 136
Patent details — US 11535869
Jurisdiction
US
Status
granted
Grant date
Dec 27, 2022
Expiration
Dec 22, 2042
Claims
30
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K2239/31
View on Google Patents ↗

Quick answer

US 11535869 (CD8-specific antibody constructs and compositions thereof) is held by Sana Biotechnology, Inc.. Status: granted. Granted Dec 27, 2022. Expires Dec 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K2239/31, A61K38/00, A61K40/11

More from Sana Biotechnology, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12427199

    Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

    RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET ANONIM SIRKETI · Expires Sep 25, 2045

    granted
  2. US 12409213

    Live attenuated oral vaccine against shigellosis and typhoid fever

    Sanaria Inc. · Expires Sep 4, 2045

    granted
  3. US 12246059

    Stable hybrid FC fusion G-CSF formulation

    ILKOGEN ILAÇ SANAYI VE TICARET A.S. · Expires Mar 6, 2045

    granted
  4. US 12171822

    Infectious plasmodium sporozoites grown in vitro

    Sanaria Inc. · Expires Dec 19, 2044

    granted
  5. US 12156870

    Antibody drug conjugates comprising sting agonists

    Mersana Therapeutics, Inc. · Expires Nov 28, 2044

    granted
  6. US 12129288

    Polynucleotides heterodimers of soluble interferon receptors and uses thereof

    Sanabio, LLC · Expires Oct 24, 2044

    granted
  7. US 12077543

    P2X3 and/or P2X2/3 compounds and methods

    Asana BioSciences, LLC · Expires Aug 29, 2044

    granted
  8. US 11987628

    Methods and compositions for modulating CAR-T activity

    Sana Biotechnology, Inc. · Expires May 16, 2044

    granted

Frequently asked questions

What is US patent 11535869?

US 11535869 (CD8-specific antibody constructs and compositions thereof) is held by Sana Biotechnology, Inc.. Status: granted. Granted Dec 27, 2022. Expires Dec 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11535869?

Sana Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.

When does US 11535869 expire?

Our index shows an expiration date of Dec 22, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.